---
title: "中国生物制药有限公司 (01177.HK)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/01177.HK.md"
symbol: "01177.HK"
name: "中国生物制药有限公司"
industry: "制药"
---

# 中国生物制药有限公司 (01177.HK)

| Item | Detail |
|------|--------|
| Industry | 制药 |
| Location | 港股市场 |
| Website | [www.sinobiopharm.com](https://www.sinobiopharm.com) |

## Company Profile

本集团业务覆盖医药各种研发平台、智能化生产和强大销售体系全产业链。其产品包括多种生物药和化学药，在肿瘤、肝病、呼吸系统疾病、外科/镇痛等多个极具潜力的治疗领域处于优势地位。

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-21T04:30:11.000Z

**Overall: B (0.37)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 3 / 48 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 10.16% |  |
| Net Profit YoY | -5.21% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 3.41 |  |
| Dividend Ratio | 1.35% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 124.76B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 33.15B |  |


**Multi Score**: B

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 11.77% | B |
| Profit Margin | 12.67% | B |
| Gross Margin | 82.47% | A |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 10.16% | B |
| Net Profit YoY | -5.21% | C |
| Total Assets YoY | 14.37% | B |
| Net Assets YoY | 10.70% | B |

#### Cash Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 789.58% | B |
| OCF YoY | 10.16% | B |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.43 | C |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 38.88% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 中国生物制药有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "11.77%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "12.67%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "82.47%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "10.16%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "-5.21%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "14.37%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "10.70%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "B",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "789.58%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "10.16%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.43",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "38.88%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 恒瑞医药 (HK.1276) | A | B | C | A | B | B |
| 02 | 翰森制药 (HK.3692) | A | B | C | A | C | B |
| 03 | 中国生物制药 (HK.1177) | B | B | C | B | B | B |
| 04 | 康哲药业 (HK.867) | B | B | C | A | B | B |
| 05 | 先声药业 (HK.2096) | B | B | B | C | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 29.39 | 26/51 | 34.25 | 29.17 | 19.42 |
| PB | 3.41 | 41/51 | 3.94 | 3.37 | 2.13 |
| PS (TTM) | 3.72 | 27/51 | 4.33 | 3.68 | 2.35 |
| Dividend Yield | 1.35% | 25/51 | 1.54% | 1.32% | 1.08% |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-19T16:00:00.000Z

Total Analysts: **25**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 19 | 76% |
| Overweight | 5 | 20% |
| Hold | 1 | 4% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 6.65 |
| Highest Target | 12.59 |
| Lowest Target | 6.16 |

## References

- [Company Overview](https://longbridge.com/en/quote/01177.HK/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/01177.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/01177.HK/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.